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ABSTRACT 
Introduction 
The rapid emergence of drug resistant bacteria is occurring worldwide, endangering the 
efficacy of antibiotics, which have transformed medicine and saved millions of lives (1-
6). Many decades after the first patients were treated with antibiotics, bacterial infections 
have again become a threat (7). The antibiotic resistance crisis has been attributed to the 
overuse and misuse of these medications, as well as a lack of new drug development by the 
pharmaceutical industry due to reduced economic incentives and challenging regulatory 
requirements. 
Materials and methods: This cross-sectional study, observational study was performed from 
January 2015 through August 2017 in the National Research Center of Mother and Child 
health, which is a tertiary care teaching hospital, in Astana, Kazakhstan. A total number of 
patients 10,000 were admitted to the Mother and Child Center annually.   The study protocol 
was approved by the Research Ethics Committee of Nazarbayev University.  All patients 
were screened for the presence of antibiotic resistant pathogens. Antibacterial therapy was 
prescribed if indicated and cultures were requested when infection was suspected. Regular 
investigations were performed following international guidelines. All personal information 
was excluded from the records. 
Results  
Out of 2,937 samples analyzed, 649 (22.10%) showed significant growth of organisms that 
exhibited multiple drug resistance. Escherichia coli was the most common MDR organism 
isolated with a total of 141 (21.73%), followed by Klebsiella pneumoniae 133 (20.49%). 
Most isolates were cultured from the throat (1,573 which is equivalent to 53.56% of total 
culture-positive samples) and urine (493 or 16.70%).  
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Categorizing specimen type distribution of samples by Hospital unit,  most of culture-positive 
samples came from urine in Mother ICU 22 (59.4%), Uronephrology 252 (64.8%) and 
Surgery Unit 23 (27.4%). In Neonatology ICU the majority of culture-positive samples were 
from blood 27 (60%). The most of pathogen-containing samples were isolated from the throat 
in Pediatric ICU 92 (23.6%), in Oncology Unit 748 (65.6%), in Rheumatology unit 246 
(92.5%), in Therapeutic unit 387 (75.7%). The majority of samples that came from cervix 
were in Gynecology unit 45 (60%). 
E. coli and Pseudomonas aeruginosa were the most common MDR pathogen isolated from 
abdominal cavity 3 (37.5%), stool 3 (30%) and urine 101 (51.3%). Pseudomonas aeruginosa 
has an increase in multidrug resistance which was 6.73% of the total number of culture-
positive for Pseudomonas aeruginosa samples isolated in 2015, 10.43% out of total number 
isolated in 2016, 19.59% out of total number isolated in 2017. Streptococcus mitis showed no 
considerable resistance to any of the antibiotics including penicillin, and was only 
4.24%.  Staphylococcus aureus was resistant to Penicillin in 97.4% cases and to Ampicillin in 
87.09% cases, Amoxicillin in 90% cases; Streptococcus epidermidis was resistant to 
Penicillin in 97.67% cases. Age distribution of multidrug resistant pathogens was equal 
among all four age groups. 0-5 years old group had 21.47% of MDR, while 5-12 years was 
24.87%, 12-18 years as 20.63%, and finally more than 18 years was 20.25%. Among all age 
groups, multidrug resistance of each pathogen also was distributed equally without any 
patterns to stand out.  
Conclusions. Based on the findings, there is a need to further research to find reasons and 
possible measures to combat increased MDR in Neonatology ICU and other hospital units 
with elevated MDR prevalence. Also, Streptococcus mitis should not be tested extensively 
for drug resistance, since the majority of isolated strains were sensitive to penicillin. Increase 
in prevalence of MDR Pseudomonas aeruginosa with time need to be closely monitored 
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further. In addition, further research is needed to confirm trends of the prevalence of MDR. 
Due to difficulties with standardized data collection, central monitoring system is necessary 
for standardized data collection and analysis 
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INTRODUCTION 
 
Antimicrobial resistance (AMR) is the development of resistance in microorganism which are 
bacteria, viruses, fungi and parasites, to an antimicrobial drug to which it was previously 
sensitive. AMR in a wide range of infectious pathogens is a growing public health threat that 
is of a great concern to countries and many sectors. The rapid rate of growth is especially 
alarming because of the global spread of multi-resistant bacteria that cause common 
infections and that resist treatment with existing antimicrobial agents (41). 
Antimicrobial resistance is an internationally recognized public health problem. The 
contribution of primary health care is particularly considerable as this is where almost 80% of 
all antibiotic agents used within the health service are prescribed (8). Resistant to antibiotics, 
bacterial infections can limit the availability of effective treatment options, altering some 
commonly encountered bacterial infections troublesome to treat, including those causing 
infections of the urinary tract. Antibiotic resistant infections also increase morbidity and 
mortality two-fold and are associated with increased healthcare costs (9). In low income 
countries, affordability of second line drugs and restricted access to healthcare can limit the 
use of newer broad-spectrum antibiotics, causing growing concerns for increased morbidity 
and mortality from antibiotic resistant infections in these countries (10). 
Children receive a lot of primary healthcare services and as such, receive a considerably high 
number of antibiotics compared with middle age groups (11). Children are also key drivers of 
infection within communities and can contribute to the spread of bacteria from person to 
person. Despite this, there is limited number of studies has been published describing the 
prevalence of bacterial resistance in children or the risk factors of importance in this group. 
In 2010, Costelloe and colleagues conducted a systematic review that reported strong 
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associations between previous encounter to routinely prescribed antibiotic agents in primary 
care and antimicrobial resistance persisting for up to 12 months (12). Most of the contributing 
studies, however, were conducted in adults. 
The antibiotic resistance associated with CA-LRTIs varies significantly depends on 
geographical locations and investigated populations (32, 33). Therefore, it is not adequate to 
simply copy the existing guidelines from other countries, which may be inappropriate and 
lead to serious problems in clinical practice (30). 
Urinary tract infections are one of the most common bacterial infections seen in primary care 
(13). In children with a suspected urinary tract infection, the most common approach is to 
treat empirically with an antibiotic while expecting for results of culture and sensitivity 
testing. Young children are more vulnerable to immediate and long-term complications, 
including renal scarring and renal failure, (14) and therefore require prompt and appropriate 
treatment. Escherichia coli is responsible for over 80% of all urinary tract infections (15) and 
is also the most common cause of bacteremia and foodborne infections and a cause of 
meningitis in neonates (16). 
Reasons for why antibiotic resistance is a concern 
 
In many other countries, antibiotics are poorly regulated and available over the counter 
without a prescription (19, 24). This lack of regulation leads to that antibiotics that are easily 
accessible, abundant, and affordable, causing overuse (24). The ability to obtain such 
products online has also made them easily accessible in countries where 
antibiotics are regulated (24). Incorrectly prescribed antibiotics also contribute to the 
promotion of resistant bacteria (5). Studies have shown that treatment indication, choice of 
agent, or duration of antibiotic therapy is incorrect in 30% to 50% of cases (5, 27). One U.S. 
study reported that a pathogen was defined in only 7.6% of 17,435 patients hospitalized with 
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community-acquired pneumonia (CAP) (23). In comparison, investigators at the Karolinska 
Institute in Sweden were able to identify the probable pathogen in 89% of patients with CAP 
through use of molecular diagnostic techniques (polymerase chain reaction [PCR] and 
semiquantitative PCR) (23). In addition, 30% to 60% of the antibiotics prescribed in intensive 
care units (ICUs) have been found to be unnecessary, inappropriate, or suboptimal (27). 
Incorrectly prescribed antibiotics have questionable therapeutic benefit and expose patients to 
potential complications of antibiotic therapy (20). Subinhibitory and subtherapeutic antibiotic 
concentrations can promote the development of antibiotic resistance by supporting genetic 
alterations, such as changes in gene expression, HGT, and mutagenesis (17). Changes in 
antibiotic-induced gene expression can increase virulence, while increased mutagenesis and 
HGT promote antibiotic resistance and spread (17). Low levels of antibiotics have been 
shown to make contribution to strain diversification in organisms such as Pseudomonas 
aeruginosa (17)
 
Discovery of new antimicrobial agents is not a solution 
 
Antibiotic development is no longer considered to be an economically beneficial investment 
for the pharmaceutical industry (23). This statement is supported by the fact that antibiotics 
are used for relatively short periods and are often curative. Furthermore, antibiotics are not as 
profitable as drugs that treat chronic conditions, such as diabetes, psychiatric disorders, 
asthma, or gastroesophageal reflux (1, 3, 22, 23). A cost–benefit analysis by the Office of 
Health Economics in London estimated that the net present value (NPV) of a new antibiotic 
agent is only about $50 million, in comparison with approximately $1 billion for a drug used 
to treat a neuromuscular disease (23). Medicines for chronic conditions are more profitable, 
for this reason pharmaceutical companies prefer to invest in them (2).  
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When new agents are eventually used, the emergence of resistance is nearly unavoidable (2). 
However, since bacterial evolution is uncertain, the timeline for the development of 
resistance is unpredictable (2). A manufacturer that invests their finances into antibiotic 
development may therefore discover that profits are prematurely curtailed when resistance 
develops to a new antibiotic (2). 
 
Among gram-positive pathogens, a global pandemic of resistant S. aureus and Enterococcus 
species currently poses the biggest threat (5, 25). MRSA kills more Americans each year than 
HIV/AIDS, Parkinson’s disease, emphysema, and homicide combined (1, 21). Vancomycin-
resistant enterococci (VRE) and a growing number of additional pathogens are developing 
resistance to many common antibiotics (1). 
Gram-negative pathogens are particularly worrisome because they are becoming resistant to 
nearly all the antibiotic drug options available, creating situations reminiscent of the pre-
antibiotic era (1, 5, 25). The emergence of MDR (and increasingly pan-resistant) gram-
negative bacilli has affected practice in every field of medicine (1). The most serious gram-
negative infections occur in health care settings and are most commonly caused by 
Enterobacteriaceae (mostly Klebsiella pneumoniae, Pseudomonas 
aeruginosa, and Acinetobacter (5, 25)). MDR gram-negative pathogens are also becoming 
increasingly prevalent in the community (25). 
MDR Pseudomonas Aeruginosa 
 
P. aeruginosa is a common cause of HAIs, including pneumonia and bloodstream, urinary 
tract, and surgical-site infections (5). More than 6,000 (13%) of the 51,000 healthcare–
associated P. aeruginosa infections that occur in the U.S. each year are MDR (25). Roughly 
400 deaths per year are attributed to these infections (5). Some strains of MDR P. 
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aeruginosa have been found to be resistant to nearly all antibiotics, including 
aminoglycosides, cephalosporins, fluoroquinolones, and carbapenems (25). 
MDR Acinetobacter baumannii 
 
Acinetobacter is a gram-negative bacterium that causes pneumonia or bloodstream infections, 
especially in critically ill patients on mechanical ventilation (5). Some Acinetobacter species 
have become resistant to all or nearly all antibiotics, including carbapenems, which are often 
considered to be the drug of last resort (5). About 12,000 health care 
acquired Acinetobacter infections occur in the U.S. each year, and 7,300 (63%) of these are 
MDR (resistant to at least three different classes of antibiotics), causing 500 deaths per year 
(5). 
Multidrug resistance definition 
 
The definition of MDR is very vague; therefore, there is a need to form clear understanding   
what MDR is in this study. In literal terms, multidrug resistance means ‘resistant to more than 
one antimicrobial agent’, but a standardized definition for MDR has not yet been agreed upon 
by the medical community. There are many definitions that are currently being utilized to 
characterize patterns. The most practical definition used for Gram-positive and Gram-
negative bacteria is ‘resistant to three or more antimicrobial classes’. Selecting Gram-
negative isolates resistant to 1
st
 and 2
nd
 line antibiotics by standard disk diffusion test was 
very difficult as isolates were from different sites which had different antibiotics in their 
1
st
 and 2
nd
 line of treatment (30). 
 
The antibiotic resistance associated with CA-LRTIs varies significantly depends on 
geographical locations and investigated populations (32, 33). Therefore, it is not adequate to 
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simply copy the existing guidelines from other countries, which may be inappropriate and 
lead to serious problems in clinical practice (30). 
 
Many different definitions for multidrug-resistant (MDR), extensively drug-resistant (XDR) 
and pandrug-resistant (PDR) bacteria are being utilized in the literature to distinguish the 
different patterns of resistance found in healthcare-associated, antimicrobial-resistant 
bacteria. A group of international experts came together through a joint initiative by the 
European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease 
Control and Prevention (CDC), to form a standardized international terminology with which 
to characterize acquired resistance profiles in S. aureus, Enterococcus spp., 
Enterobacteriaceae (other than Salmonella and Shigella), P. aeruginosa and Acinetobacter 
spp., all bacteria often responsible for healthcare-associated infections and incline to become 
multidrug resistant. Epidemiologically significant antimicrobial categories were constructed 
for each bacterium. Lists of antimicrobial categories proposed for antimicrobial susceptibility 
testing were created using documents and breakpoints from the Clinical Laboratory Standards 
Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) and the United States Food and Drug Administration (FDA). MDR was defined 
as acquired non-susceptibility to at least one agent in three or more antimicrobial categories, 
XDR was defined as non-susceptibility to at least one agent in all but two or fewer 
antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two 
categories) and PDR was defined as non-susceptibility to all agents in all antimicrobial 
categories. To ensure correct application of these definitions, bacterial isolates should be 
tested against all or nearly all of the antimicrobial agents within the antimicrobial categories 
and selective reporting and suppression of results should be avoided (34). 
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Global monitoring systems of antimicrobial resistance 
 
Information to monitor and manage this spread exists in the susceptibility test results of tens 
of thousands of laboratories worldwide. The comparability of those results is uncertain, 
however, and their storage in paper files or in computer files with diverse codes and formats 
has made them inaccessible for analysis. The WHONET program puts each laboratory's data 
into a common code and file format at that laboratory, either by serving as or by translating 
from its own computer reporting system. It then empowers each medical center to analyze its 
files in ways that help it monitor and manage resistance locally and to merge them with files 
of other centers for collaborative national or global surveillance of resistance (35). Such data 
management strategy is currently lacking in Kazakhstan. 
The Global Antimicrobial Resistance Surveillance System (GLASS) is being developed to 
support the Global Action Plan on Antimicrobial Resistance and should be coordinated 
within the national action plans of countries. The goal of GLASS is to enable standardized, 
comparable and validated data on AMR to be collected, analyzed and shared with countries, 
in order to inform decision-making, drive local, national and regional action and provide the 
evidence base for action and advocacy (36). 
Even though Kazakhstan is a member or participant in global resistance monitoring systems, 
there is no reports on antimicrobial resistance situation available. The implementation of the 
monitoring systems is in progress at the moment. Furthermore, there is lack of published data 
on antibiotic resistance topic in Kazakhstan.  
 
 
AIM OF THIS STUDY 
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This study aims to analyze patterns of the common pathogens in the Mother and Child 
Hospital in Astana, Kazakhstan. For establishing these patterns, the study is developed to find 
associations between multidrug resistance and 4 variables at the study site such as type of 
pathogen, hospital unit, type of specimens, age. Based on the findings, the study will form 
guidelines to provide recommendations for antimicrobial stewardship programs in the Mother 
and child hospital. Furthermore, the study aims to provide guidance for effective antibiotic 
choice. By implementing antimicrobial stewardship program, the ultimate goal is to minimize 
the development of antimicrobial and multidrug resistance. 
 
METHODS 
 
An observational study was conducted for a period of 2 years and 8 months from January 
2015 to August 2017 in a tertiary care hospital in Astana, Kazakhstan. Approval from the 
Institutional Research and Ethical committee was obtained prior to the commencement of the 
study. Data regarding culture and sensitivity of the organisms isolated from different sources 
such as urine, blood, pus/wound/skin, stool, sputum, cervix, nose swabs were collected from 
the records of the State Diagnostic Center (Microbiology laboratory). Sample processing, 
identification of organisms to the genus and/or species level and antimicrobial sensitivity 
were carried out as per the Clinical and Laboratory Standards Institute guidelines on the 
2,937 samples received. 
Data collection 
 
A cross-sectional observational study was conducted between January 2015 and August 
2017. The initial number of medical records was close to 7000. Due to errors in data entry 
(mostly because of non-standard methods of data collection), many records not relevant to 
this study were omitted.  
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Some samples were tested for the presence of drug resistance for certain antibiotics, other 
samples for another antibiotic. Each individual pathogen has been tested for a particular set of 
antibiotics, but not all for the antibiotics in this set.  In other words, the number of samples of 
a certain pathogen varied across different antibiotics. 
Age-stratification was done by 5-7 years in order to make each age group similar in the 
number of participants as well to have biological similarities. 
Inclusion criteria 
 
The inclusion criteria were that the patients are only from Mother and Child Center. Initial 
data consisted of over 40 pathogens, but due to small number of representatives for each 
pathogen (small sample size) these were deleted from this study. Only 12 pathogens were 
included in the study as they had sample size enough to perform statistical analysis to obtain 
statistical significance. Samples that were culture-positive for 12 pathogens were included in 
the study. In addition, age was the inclusion criteria, though many medical records contained 
incorrect age. Also, Mother and Child Health Center has over 20 hospital units, data from 
some of the units were combined in one category. For example, data from urology, 
nephrology and kidney center were combined into one Uronephrology unit category. There 
are 4 different oncology units that data were combined into one oncology unit category. In 
the Mother and Child health center, data from obstetrics and gynecology units was combined 
into one gynecology unit category.  
Due to inconsistency in data entry, specimens were named differently. By researcher’s 
judgement, main categories were established. As an example, nasal swab, nose, nostrils, nasal 
discharge was combined into one category “nose”. Many medical records were deleted as 
they could not be attributed to any of the categories such as drainage, since no clear 
information was available about the exact location where the drainage came from. 
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Exclusion criteria 
 
Culture-positive for pathogens not selective for this study, or negative culture were deleted. 
Also, repetitive testing is a normal practice for hospitals. These medical records were also 
excluded from the study, as they inflated the number of culture-positive and/or multidrug 
resistant samples leading to incorrect results.  
Secondary data was used for this study. The data entry occurred as the Department of 
Infection Control in Mother and Child Health Center had access to the medical records. It 
contained laboratory testing results with the pathogen that the patient was positive to, and 
antibiotics that the pathogen was either sensitive, resistant or intermediate. Intermediate were 
assumed as resistant, since some of the resistance was present though not to the full extent. 
These laboratory testing records were collected into one database for further analysis on 
prevalence, distribution and antimicrobial resistance monitoring. 
 
 
Sample 
 
All medical records belong to the Mother and Child Center patients. The results obtained 
were of samples from patient blood, urine, nose, throat testing results. These samples were 
from patients from all hospital units of Mother and Child Center. Age of the participants were 
in the range of 0-47 years. Convenience sampling was used to collect data. As it was 
discussed above, only those records that were available with full set of information were 
included. Sample size contained 2,937 of culture-positive samples, whereby out of this 
number, 649 of these pathogens were multidrug resistant. 
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No tentative sample size calculation was made, since the sampling was convenient. In other 
words, all medical records that met the study requirements were included in the study.  
Also, there is important to note that the cutoff level for the pathogen was established as 50 
counts. This was done for the purpose of feasibility of the study as much as obtain statistical 
significance. 
 
Statistical analysis 
STATA SE 12.0 package was used for frequencies and percentage for categorical variables, 
chi square. Poisson regression with robust equal variance was used to establish the 
association of multidrug resistance development and types of hospital units. 
Variables  
Dependent variable was the presence or absence of multidrug resistance while the 
Independent variables were pathogen types, specimen type, hospital units, and patients’ age 
(in years). 
Antibiotics tested for sensitivity against gram negative bacteria were erythromycin, 
penicillin, oxacillin, clarithromycin, ampicillin, cefazolin, gentamycin, azithromycin, 
amoxicillin, ceftazidime, piperacillin, clindamycin, trimethoprim, vancomycin, doxycycline, 
tetracycline, piperacillin, linezolid, amoxicillin, cefepime, cefotaxime, meropenem, 
ceftriaxone, ertapenem, aztreonam, amikacin, imipenem, ciprofloxacin, cefuroxime, 
ticarcillin, levofloxacin, lomefloxacin, moxifloxacin, tobramycin, minocycline, norfloxacin, 
chroramphenicol, and ofloxacin.  
 
Organisms considered to be multidrug resistant to Gram-positive and Gram-negative bacteria 
is ‘resistant to three or more antimicrobial classes’. Selecting Gram-negative isolates resistant 
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to 1
st
 and 2
nd
 line antibiotics by standard disk diffusion test was very difficult as isolates were 
from different sites which had different antibiotics in their 1
st
 and 2
nd
 line of treatment (30). 
 
ETHICS 
No personally identifiable data was obtained during the study. After getting an informed 
consent from the subjects, they were requested to answer a simply formulated questionnaire 
to the fullest of their knowledge to elicit their prior antibiotic history. Other relevant data was 
obtained from the patient's case sheet.  
 
RESULTS 
The total number of samples sent to the microbiology laboratory from Mother ICU, 
Neonatology ICU, Pediatric, Uronephrology, Gynecology, Oncology, Therapeutic, 
Rheumatology, Surgery units for culture and sensitivity during the period from January 2015 
to August 2017 was 2,937 samples. Out of this (TABLE 1), 37 (1.26%) samples were from 
patients hospitalized in Mother ICU, 45 (1.53%) from Neonatology ICU, 390 (13.28%) from 
Pediatric ICU, 389 (13.24%) from Uronephrology unit, 75 (2.55%) from Gynecology unit, 
1140 (38.82%) from Oncology unit, 266 (9.06%) from Rheumatology unit, 511 (17.4%) from 
Therapeutic unit, 84 (2.86%) from Surgery Unit. Out of 2,937 samples, 649 (22.10%) showed 
significant growth of organisms exhibiting multiple drug resistance. Out of these, 20 were 
(3.08%) from Rheumatology unit, 9 (1.4%) from Mother ICU, 31 (4.78%) from Neonatology 
unit, 146 (22.5%) from Pediatric unit, 132 (20.34%) from Uronephrology unit, 12 (1.85%) 
from Gynecology unit, 182 (28.04%) Oncology unit, 78 (12.02%) from Therapeutic unit, and 
39 (6%) from Surgery unit. 
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Streptococcus mitis was the most common isolate (1085 (36.96%)), Staphylococcus aureus 
(389 (13.24%)), Staphylococcus epidermidis (230 (7.83%)), Escherichia coli (222 (7.56%)), 
Candida albicans (208 (7.08%)), Pseudomonas aeruginosa (198 (6.74%)), Klebsiella 
pneumoniae (193 (6.57%)), Enterococcus faecalis (188 (6.4%)), Acinetobacter baumannii 
(83 (2.83%)), Streptococcus pneumoniae (50 (1.7%)), Candida tropicalis (50 (1.7%)), and 
Stenotrophomas maltophilia (41 (1.4%)) (Table 2).  Escherichia coli was the most common 
MDR organism isolated with a total of 141 (21.73%), followed by Klebsiella pneumoniae 
(133 (20.49%)), Staphylococcus epidermidis (109 (16.8%)), Pseudomonas aeruginosa (73 
(11.25%)), Staphylococcus aureus (73 (11.25%)), Acinetobacter baumannii (29 (4.47%)), 
Candida albicans (27 (4.16%)), Stenotrophomonas maltophilia (24 (3.7%), Enterococcus 
faecalis 18 (2.77%)), Candida tropicalis (10 (1.54%)), Streptococcus mitis (12 (1.85%)), and 
Streptococcus pneumoniae showed no multidrug resistance.  
In Mother ICU, the most common isolate was E. coli (10 (27%)), while Staphylococcus 
epidermidis was14 (31%)), in Neonalogy ICU, Pseudomonas aeruginosa was 62 (16%) in 
Pediatric ICU and 15 (17.86%) in Surgery unit, E. coli was 93 (23.9%) in Uronephrology, 
Enterococcus faecalis was 27 (36%) in Gynecology, Streptococcus mitis was 578 (50.7%) in 
Oncology unit and 251(49%) in Therapeutic unit, and 136 (51%) in Rheumatology unit 
(Table 3) 
Most isolates were cultured from the throat with 1,573 (53.56%), urine was 493 (16.70%), 
nose 197 (6.71%), blood 166 (5.65%), and wound/skin/pus 152 (5.18%), following intubation 
tube, sputum, cervix, subclavian catheter, urine catheter, nasogastric tube, stool, abdominal 
cavity (Table 4). Most MDR isolated were cultured from urine which == (30.35%), throat 
138 (21.26%), blood 83 (12.79%), pus/wound/skin 51 (7.86%), intubation tube 45 (6.93%), 
nose 44 (6.78%) following subclavian catheter, sputum, nasogastric tube, urine catheter, 
abdominal cavity, breast milk, cervix, stool. 
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Streptococcus mitis was cultured from the throat with 1017 (64.7%) and sputum was 31 
(40.8%), Enterococcus faecalis from cervix was 27 (49%), urine catheter was 10 (32.3%), E. 
coli from abdominal cavity was 5 (41.7%), stool 5 (27.8%), urine 160 (32.5%), Pseudomonas 
aeruginosa from intubation tube 24 (27.6%) and nasogastric tube 7 (31.8%), Staphylococcus 
aureus from nose 85 (43.1%) and pus/skin/wound 40 (26.3%), Staphylococcus epidermidis 
from blood 65 (39.2%), subclavian catheter 20 (41.5%) (Table 5). 
Most of culture-positive samples came from urine in Mother ICU (22 (59.4%)), 
Uronephrology (252 (64.8%)), Surgery Unit (23 (27.4%)); in Neonatology ICU from blood 
(27 (60%)); from the throat in Pediatric ICU (92 (23.6%)), in Oncology Unit (748 (65.6%)), 
in rheumatology unit (246 (92.5%)), in Therapeutic unit (387 (75.7%)); and from cervix in 
Gynecology unit was 45 (60%) (Table 6). 
In Mother ICU, the most common MDR isolate was Escherichia coli 3 (33%) in 
Uronephrology 64 (48.5%) and Gynecology 4 (33.3%), Klebsiella pneumoniae in Pediatric 
ICU 33 (22.6%) and Oncology unit 39 (21.5%), Pseudomonas aeruginosa 14 (35.9%) in 
Surgery unit, Staphylococcus aureus in Therapeutic unit 19 (24.4%) and Rheumatology 14 
(70%), Staphylococcus epidermidis in Neonatology ICU 11 (35.5%) and Oncology unit 40 
(22%) (TABLE 7). 
E. coli and Pseudomonas aeruginosa were the most common MDR pathogen isolated from 
abdominal cavity (3 (37.5%)), stool (3 (30%)) and urine (101 (51.3%)); MDR K. pneumoniae 
from subclavian catheter (9 (33.3%)) and ng tube (3 (27.2%)), MDR Staphylococcus 
epidermidis from blood (50 (60.24%)) and nose (20 (45.45%)), MDR Staphylococcus aureus 
from throat (45 (32.6%)), MDR Pseudomonas aeruginosa from intubation tube (15 (33.3%)), 
urine catheter (5 (55.6%)), and sputum (4 (28.57%)) (Table 8). 
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In Rheumatology unit (16 (80%)), in oncology unit (50 (27.5%)), (41 (52.6%)) in 
Therapeutic unit from the throat of samples contained MDR pathogens, in Neonatology ICU 
(18 (58%)) from blood, in Pediatric ICU (24 (16.4%)) from urine, in Uronephrology Unit 
(112 (84.8%)) from urine, in gynecology unit (7 (58.3%)), in surgery unit (11 (28.2%)) from 
pus/wound/skin (Table 9). 
 
(Figure 1 and Table 15) Looking at the dynamics in each pathogen separately, there is a drop 
in Multidrug resistance of S. mitis from 4.48% in 2015, 0.72% in 2016 to 0% in 2017; of 
Candida albicans from 8.52% in 2015, 2.52% in 2016 to 0.68% in 2017, Enterococcus 
faecalis showed some drop from 5.38% (2015) to 1.08% (2016), and relatively little increase 
of 2.03% in 2017. Pseudomonas aeruginosa had an increase in multidrug resistance which 
was 6.73% in 2015, 10.43% in 2016, 19.59% in 2017. The rest of the pathogens did not 
demonstrate any either positive or negative dynamism. Limitation was that with only 2.5 
years study, this was not long enough a period of time to notice remarkable changes.  
Drug-specific resistance  
(Table 10) Streptococcus mitis showed no considerable resistance to any of the antibiotics 
including penicillin, which only 4.24%.  Streptococcus pneumoniae was sensitive to almost 
all antibiotics tested for sensitivity, except  against Trimetoprim/sulfomethoxazol with 40% 
resistance. Enterococcus faecalis demonstrated the highest resistance to Norfloxacin (25%) 
and Penicillin (18.33%); Staphylococcus aureus resistant to Penicillin in 97.4% cases and to 
Ampicillin in 87.09% cases, Amoxicillin in 90% cases; Streptococcus epidermidis is resistant 
to Penicillin in 97.67% cases, to Erythromycin in 50% tests, and to Clarithromycin, 
Trimetoprim/Sulfomethoxazol, Azithromycin approximately in 48% cases. 
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(Table 11) Acinetobacter baumannii was resistant in 1/3 cases to ceftazidime, 
trimethoprim/sulfomethoxazol, piperacillin, ampicillin/sulfomethoxazol, cefepime, 
cefuroxime, ceftriaxone, and in 44.44% cases for ticarcillin/clavulanate.  
E. coli was resistant in 97 % to ampicillin and amoxicillin, in about 60-70% of cases to 
cefazolin, piperacillin, ampicillin/sulfomethoxazol, amoxicillin/clavulanate, 
ticarcillin/clavulanate, trimethoprim. 
Klebsiella pneumoniae was resistant to ampicillin in 99.48% and 100% to amoxicillin, 
approximately 70-80% cases to cefazolin, piperacillin, amoxicillin/clavulanate, 
ampicilline/sulfomethoxazol, cefuroxime, ticarcillin/clavulanate. 
Pseudomonas aeruginosa appeared to be resistant to ceftazidime in 44.57%, gentamycin 
34.57%, piperacillin in 32.95%, cefepime 32.82%. 
Stenotrophomas maltophilia was resistance to ticalrcillin/clavulanate in 76.92% and to 
ceftazidime in 60% cases. 
(Table 12) For yeast infections such as Candida albicans and Candida tropicalis less 
resistance was for Amphotericin 1.13% and 11.63% respectively, and no resistance to 
nystatin. 
(Table 13) Age distribution of multidrug resistant pathogens was equal among all four age 
groups. 0-5 years old 21.47%, 5-12 years 24.87%, 12-18 years 20.63%, more than 18 years 
20.25% Among all age groups, multidrug resistance of each pathogen also was distributed 
equally without any patterns to stand out. Contingency table indicates p-value of 0.161 
meaning that no association between developing drug-resistance and patients’ age. 
 
(Table 14) Rheumatology unit has the lowest prevalence of MDR therefore it was selected as 
reference to compare with MDR prevalence in other hospital units. The results of Poisson 
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regression indicated that Neonatology ICU has 9 times more MDR prevalence , 6 times more 
in Surgery Unit, almost 5 times more in Pediatric ICU than in Rheumatology Unit. 
 
Maximum resistance was observed with commonly used first line antimicrobials such as co-
trimoxazole, penicillin, ampicillin, amoxicillin, amoxiclav, piperacillin. Least resistance was 
observed in third generation cephalosporins, fluoquinolones, meropenem, linezolid, 
amikacin, vancomycin. 
 
DISCUSSION 
The results obtained are discussed below categorized by the pathogens selected for this study. 
1) Streptococcus mitis was the most common culture-positive isolate 1,085 (36.84%). It has 
one of the least MDR prevalence rate (1.1%). St. mitis has only 4.24% resistance to 
Penicillin, making this antibiotic is a good choice for treating patients with St. mitis caused 
infections. St. mitis was mostly isolated from the throat. This pathogen is leading in culture-
positive isolates in Rheumatology (51%), Oncology (50.7%) and Therapeutic (49%) units.  
 
2) Klebsiella pneumoniae. Leading pathogen in MDR is Klebsiella pneumoniae (68.91%). It 
was MDR in 133 cases out of 193 culture-positive isolates. Most isolates came from blood 
(16) and wound/pus/skin (13) specimens. Out of 16 samples from blood 13 appeared to be 
MDR. The majority (51) of Kl. pneumoniae positive culture are from Oncology unit. Out of 
51, 39 (76.4%) are multidrug resistant. In Neonatology ICU 8 out of 9 Kl. pneumoniae-
positive are MDR, making the researchers pay special attention about the procedures in 
Neonatology ICU that contribute to the excessive level of multidrug resistance. 
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3) Pseudomonas aeruginosa showed the greatest increase in multidrug resistance from 6.73% 
in 2015, 10.43% in 2016, 19.59% in 2017. It has resistance to Ceftazidime 44.57%, and 
relatively high resistance to 4
th
 generation of antibiotics (cefepime, piperacillin). Moreover, 
least resistance to a complex antibiotic Piperacillin/Tazobactam 11.35% and Norfloxacin 
(9.52%) and Ciprofloxacin (15.3%). This pathogen is the most common culture positive 
samples from Pediatric (15.9%) and Surgery (17.9%) units. Out 39 culture-positive samples 
for P. aeruginosa, 14 are multidrug resistant in Surgery Unit. In 55% cases P. aeruginosa 
appeared to be resistant from swabs taken from urine catheters. 
4) Escherichia coli is the most frequent isolate which possesses MDR 21.73% of all MDR 
isolates, the majority of samples are from urine in Uronephrology unit. Similar tendency was 
described in Russia [47]. Multidrug resistant in 141 out of 222 culture positive isolates 
making 63.5% resistance. Highly resistant to many antibiotics including ampicillin (97.7%), 
amoxicillin (97.27%), ticarcillin/clavulanate (70.77%). Drugs of choice to treat culture-
positive is piperacillin/tazobactam (1.4%), carbapenems (1.5-2.5%).  This pattern of 
resistance has been shown by many studies. [42,43,44,46] 
 
5) Staphylococcus aureus is most common isolate from nose (43.1%), but only 8 out of 83 
are MDR (9.6%). Isolated from pus/skin/wound 26.3%, but only 3 out 40 are MDR (7.5%). 
Out of 197 isolated, from the throat 45 are MDR (22.8%). The conclusion is that the St. 
aureus isolated from the throat tend to be more resistant to multiple antibiotics. St. aureus 
comprises 70% of MDR pathogens in Rheumatology unit. St. aureus is in a great extent 
(~90%) resistant to penicillin, ampicillin, amoxicillin, whereas low resistance to 
erythromycin, gentamycin and azithromycin, making them drugs of choice for treatment. 
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6) Staphylococcus epidermidis comprises 60.24% of all MDR pathogens from blood are 
positive for St. epidermidis. Out of 65 culture-positive samples, 50 are MDR (76.9%). Out of 
31 all MDR, 18 contain MDR St. epidermidis, making Neonatology Unit a leader (58%) in 
MDR St. epidermidis positive samples. According to logistic regression, Neonatology unit 
has 27 times more MDR that Rheumatology Unit. Blood samples with MDR St. epidermidis 
are main contributors to the aforementioned association. The highest resistance to penicillin 
97.67% with relatively elevated resistance to many other available antibiotics ranging from 
35% to 50% (erythromycin, clarithromycin, azithromycin, trimethoprim/sulfamethoxazole, 
doxycycline, tetracycline, chloramphenicol). Drugs of choice for treatment with low 
resistance are gentamycin, vancomycin, linezolid, moxifloxacin). 
 
7) Acinetobacter baumannii. Out of 83 culture-positive samples for this pathogen, 29 
demonstrated multidrug resistance. The highest prevalence of resistance was noticed from 
intubation tube swabs. 5 out 6 A. baumannii are MDR. More than 1/3 of all MDR A. 
baumannii is from Pediatric ICU. Out of 28 samples with A.baumannii, 13 are MDR 
(46.4%). This pathogen has resistance to third generation of cephalosporins (~35%), the 
highest resistance to ticarcillin/clavulanate (44.44%), the lowest to amikacin (4.94%). 
 
8) Enterococcus faecalis Out of 188 culture-positive, 18 are MDR. Gynecology unit has 36% 
E. faecalis of all culture-positive samples, the good sign is that only one out of 27 is 
multidrug resistant. Also, there is notable decrease in MDR over time from 5.38% multidrug 
resistant in 2015, 1.08% in 2016 and 2.03% in 2017.  Resistance to ampicillin and 
amoxicillin ~9%. The greatest prevalence of resistance to norfloxicin (25%) and tetracycline 
(19.75%). Least prevalence of resistance to vancomycin and linezolid ~5%. This percentage 
gave us the reason to consider Ent. faecalis as relatively easy to choose antibiotic therapy. 
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9) Streptococcus pneumoniae 
No MDR was found, according to the criteria of this study to be considered as MDR. The 
greatest resistance 40% trimethoprim/sulfamethoxazole. The resistance to penicillin is only 
12% and less with erythromycin and doxycycline. 
 
 
10) Stenotrophomas maltophilia  The sample size of MDR pathogens was 41, but this 
particular pathogen was included into the study due to high resistance frequency. Out of 109 
culture-positive samples, 41 appeared to be MDR. Out of 23 culture-positive for St. 
maltophilia, 13 are MDR in Pediatric ICU. Most samples came from intubation tube swabs, 7 
out 11 swabs are MDR. Most resistant to ticarcillin/clavulanate 76.92% and ceftazidime 60%, 
least resistant to levofloxacin 0% and trimethoprim/sulfomethoxazole 2.5%. 
 
11) Candida albicans and Candida tropicalis Out of 208, 27 were MDR Candida albicans 
making this pathogen be multidrug resistance in 13% cases. Candida tropicalis was MDR in 
20% cases (out of 50 culture-positive, 10 was multidrug resistant). The is a noticeable drop in 
resistance over time in Candida albicans from 8.52% in 2015, 2.52% in 2016 and 0.68 in 
2017. Both pathogens are more (15-35%) resistant to imidazoles and triazoles, less (0-1%) 
resistant to Polyenes (Nystatin, Amphotericin). 
 
Global trends 
As with global trends, where Pseudomonas aeruginosa showed increase of Multidrug 
resistance in time according to (37, 38); similar dynamics was obtained from this study. 
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E.coli showed the greatest prevalence among multidrug resistant pathogens which aligned 
with global trends (39). 
Similar to global trends, ICU units are the epicenters for multidrug resistance in Mother and 
Child Health Center (40). 
 
Strengths 
The sample size of this study was large which allowed us to obtain results with statistical 
significance without any manipulation. Importantly, large number (n>50.) of important 
pathogens were isolated. Pathogens were tested for a great number (n=60) of antibiotic 
sensitivity/resistance. 
No similar studies have been published in Kazakhstan at the time of conducting the study  
Limitations 
This study was conducted only in one hospital. Regrettably, no data whether patients were 
taking antibiotic before the tests for antibiotic sensitivity were available, since antibiotics are 
easily available over-the-counter medications. Similarly, no previous history of antibiotic use 
was available as it is the main factor for antimicrobial resistance development. Relatively 
short period of time (2.5 years only) during the study was insufficient to show trends that 
reflect the true scenario. Major inconsistency was found in the dataset during data 
management and analysis, thus mistakes and errors might be erosive for the reliability of 
results. 
 
CONCLUSION AND RECOMMENDATIONS 
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The findings of this study show that there is a need for further research to find reasons and 
possible measure to combat increased MDR in Neonatology ICU and other hospital units 
with elevated MDR prevalence. One recommendation is that Streptococcus mitis should not 
be tested extensively for drug resistance, since the majority of results are sensitive to 
penicillin. There are expenses involved in testing that are not effectively used.  
Increase in prevalence of MDR Pseudomonas aeruginosa with time need to be closely 
monitored further. As with the global trends, the MDR prevalence of this pathogen rises, 
monitoring will help to trace the trend further.  
In addition, the necessity to implement central system of gathering and monitoring data of 
antibiotic/antimicrobial resistance such as CAESAR or GLASS (in Europe or the world 
respectfully). As working with not standardized data might reveal incorrect or false results. 
 
APPENDIX 
 
 Table 1 Distribution of pathogens by Hospital Unit 
  
Distribution of pathogens by Hospital 
Unit 
Culture-positive 
(n/%) 
Multidrug 
resistant  
(n/%) 
Mother ICU 37/1.26 9/1.39 
Neonatology  ICU 45/1.53 31/4.78 
Pediatric ICU 390/13.48 146/22.5 
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Uronephrology 389/13.42 132/20.34 
Gynecology 75/2.55 12/1.85 
Oncology 1140/38.82 182/28.04 
Therapeutic unit 511/17.4 78/12.02 
Surgery 84/2.86 39/6.01 
Rheumatology 266/9.06 20/3.08 
Total 2937/100 649/100 
 
Figure 2 Distribution of culture-positive samples by Hospital Unit 
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Figure 3 Distribution of multidrug resistant pathogens by Hospital Unit 
 
 
 
Table 2 Distribution of culture-positive and multidrug resistant pathogens  
  
Distribution of 
pathogens 
Culture-
positive 
(n/%) 
Multidrug 
resistant 
(n/%) 
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Acinetobacter 
baumannii 
83/2.83 29/4.47 
Candida albicans 208/7.08 274.16 
Candida tropicalis 50/1.7 10/1.54 
Enterococcus 
faecalis 
188/6.4 18/2.77 
Escherichia coli 222/7.56 141/21.73 
Klebsiella 
pneumoniae 
193/6.57 133/20.49 
Pseudomonas 
aeruginosa 
198/6.74 73/11.25 
Staphylococcus 
aureus 
389/13.24 73/11.25 
Staphylococcus 
epidermidis 
230/7.83 109/16.8 
Stenotrophomonas 
maltophilia 
41/1.4 24/3.7 
Streptococcus 
mitis 
1085/36.94 12/1.85 
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Streptococcus 
pneumoniae 
50/1.7 0/0 
Total 2937/100 649/100 
 
 
Figure 4 Distribution of culture-positive samples 
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Figure 5 Distribution of multidrug resistant pathogens 
 
 
  Table 3 Distribution of pathogens by Hospital Unit  
35 
 
Distribution of 
pathogens by 
Hospital Unit 
Mot
her 
ICU 
Neon
atolo
gy 
ICU 
Pedi
atric 
ICU 
Uron
ephr
olog
y 
Gyn
ecolo
gy 
Onc
olog
y 
Ther
apeu
tic 
Unit 
Rhe
umat
olog
y 
Surg
ery 
Tota
l 
Acinetobacter 
baumannii 4 3 28 6 1 30 7 0 4 83 
Candida albicans 7 2 44 12 6 65 58 9 5 208 
Candida 
tropicalis 0 0 20 5 2 13 10 0 0 50 
Enterococcus 
faecalis 5 5 37 45 27 47 10 5 7 188 
Escherichia coli 10 7 23 93 15 46 10 6 12 222 
Klebsiella 
pneumoniae 3 9 40 44 4 51 22 11 9 193 
Pseudomonas 
aeruginosa 0 3 62 37 0 54 16 11 15 198 
Staphylococcus 
aureus 5 0 27 42 14 135 75 81 10 389 
Staphylococcus 
epidermidis 3 14 40 31 4 97 28 3 10 230 
Stenotrophomona
s maltophilia 0 0 23 5 0 9 2 0 2 41 
Streptococcus 
pneumoniae 0 0 6 3 0 15 22 4 0 50 
Streptococcus 0 2 40 66 2 578 251 136 10 1085 
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mitis 
Total 37 45 390 389 75 1140 511 266 84 2937 
 
Table 4 Distribution of pathogens by Specimen type 
  
Distribution of 
pathogens by 
Specimen type 
Culture-
positive 
(n/%) 
Multidrug-
resistant 
(n/%) 
abdominal cavity 12/0.41 8/1.23 
blood 166/5.65 83/12.79 
breast milk 2/0.07 1/0.15 
cervix 55/1.87 11/1.69 
intubation tube 87/2.96 45/6.93 
nasogastric tube 22/0.75 11/1.69 
nose 197/6.71 44/6.78 
pus/wound/skin 152/5.18 51/7.86 
sputum 76/2.59 14/2.16 
stool 18/0.61 10/1.54 
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subclavian catheter 53/1.8 27/4.16 
throat 1573/53.56 138/21.26 
urine 493/16.79 197/30.35 
urine catheter 31/1.06 9/1.39 
Total 2937/100 649/100 
 
 
    
Table 5 Distribution of culture-positive pathogens by Specimen type  
Distribution of 
culture-positive 
pathogens by 
Specimen type 
abdo
mina
l 
cavit
y 
bloo
d 
breas
t 
milk 
cervi
x 
intub
ation 
tube 
naso
gastri
c 
tube nose 
pus/
woun
d/ski
n 
sputu
m stool 
subcl
avian 
cathe
ter 
throa
t urine 
urine 
cathe
ter Total 
Acinetobacter 
baumannii 0 6 1 1 6 4 9 5 6 1 2 38 4 0 83 
Candida albicans 0 10 0 4 7 1 7 4 9 3 1 113 47 2 208 
Candida 
tropicalis 1 10 0 2 0 0 0 1 1 0 1 17 16 1 50 
Enterococcus 
faecalis 1 15 0 27 2 1 1 18 1 1 5 19 87 10 188 
Escherichia coli 5 7 0 9 6 2 5 10 2 5 4 4 160 3 222 
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Klebsiella 
pneumoniae 1 16 0 4 9 3 7 13 6 2 9 53 68 2 193 
Pseudomonas 
aeruginosa 3 17 0 0 24 7 7 13 6 3 1 56 42 8 198 
Staphylococcus 
aureus 1 9 0 7 10 0 85 40 6 1 7 197 25 1 389 
Staphylococcus 
epidermidis 0 65 1 1 7 1 52 29 1 1 22 12 34 4 230 
Stenotrophomona
s maltophilia 0 4 0 0 11 2 0 5 2 1 1 11 4 0 41 
Streptococcus 
pneumoniae 0 0 0 0 1 0 8 4 1 0 0 36 0 0 50 
Streptococcus 
mitis 0 7 0 0 4 1 15 4 31 0 0 1017 6 0 1085 
Total 12 166 2 55 87 22 197 152 76 18 53 1573 493 31 2937 
 
  
Table 6 Sample distribution of pathogens by Hospital Unit 
Sample 
distribution 
of pathogens 
by Hospital 
Unit  
Mot
her 
ICU 
Neo
nato
logy 
ICU 
Pedi
atric 
ICU 
Uro
neph
rolo
gy 
Gyn
ecol
ogy 
Onc
olog
y 
Ther
apeu
tic 
Unit 
Rhe
uma
tolog
y 
Surg
ery 
Tota
l 
abdominal 
cavity 0 1 5 0 0 3 0 1 2 12 
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blood 12 27 41 7 2 48 25 1 13 166 
breast milk 1 0 0 0 0 0 0 0 1 2 
cervix 1 0 3 0 45 1 3 1 1 55 
intubation 
tube 2 2 56 4 0 21 0 0 2 87 
nasogastric 
tube 0 0 15 2 0 3 1 0 1 22 
nose 0 3 46 23 0 118 8 2 7 197 
pus/wound/ski
n 3 3 26 5 6 71 20 4 14 152 
sputum 4 1 17 11 1 10 26 4 2 76 
stool 0 1 12 2 0 2 0 0 1 18 
subclavian 
catheter 2 2 14 0 0 29 6 0 0 53 
throat 0 4 92 77 3 748 387 246 16 1573 
urine 22 0 52 252 18 86 33 7 23 493 
urine catheter 0 1 21 6 0 0 2 0 1 31 
Total 37 45 390 389 75 1140 511 266 84 2937 
 
 
 
Table 7 Distribution of multidrug resistant pathogens by Hospital Unitpathogens by H 
Distribution of 
multidrug 
pathogens by 
Mot
her 
ICU 
Neo
nato
logy 
Pedi
atric 
ICU 
Uro
nep
hrol
Gyn
ecol
ogy 
Onc
olog
y 
The
rape
utic 
Rhe
uma
tolo
Sur
gery 
Tot
al 
40 
 
Hospital Unit  ICU ogy Unit gy 
Acinetobacter 
baumannii 2 3 13 2 0 7 1 0 1 29 
Candida 
albicans 0 0 7 0 0 6 12 2 0 27 
Candida 
tropicalis 0 0 6 1 1 1 1 0 0 10 
Enterococcus 
faecalis 1 0 2 4 1 8 1 0 1 18 
Escherichia coli 3 7 16 64 4 32 4 3 8 141 
Klebsiella 
pneumoniae 1 8 33 29 1 39 13 0 9 133 
Pseudomonas 
aeruginosa 0 2 25 13 0 16 3 0 14 73 
Staphylococcus 
aureus 1 0 7 7 2 23 19 14 0 73 
Staphylococcus 
epidermidis 1 11 24 7 3 40 17 1 5 109 
Stenotrophomon
as maltophilia 0 0 13 4 0 5 1 0 1 24 
Streptococcus 
pneumoniae 0 0 0 0 0 0 0 0 0 0 
Streptococcus 0 0 0 1 0 5 6 0 0 12 
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mitis 
Total 9 31 146 132 12 182 78 20 39 649 
ospital Unit  
 
Table 8 Distribution of multidrug resistant pathogens by Specimen type 
Distribution of 
multidrug 
resistant 
pathogens by 
Specimen type 
abdo
mina
l 
cavit
y 
bloo
d 
brea
st 
milk 
cervi
x 
intu
batio
n 
tube 
naso
gastr
ic 
tube nose 
pus/
wou
nd/s
kin 
sput
um stool 
subcl
avia
n 
cath
eter 
thro
at 
urin
e 
urin
e 
cath
eter 
Tota
l 
Acinetobacter 
baumannii 0 3 0 0 5 1 4 2 2 0 1 10 1 0 29 
Candida albicans 0 1 0 0 1 0 0 0 2 1 0 17 5 0 27 
Candida 
tropicalis 0 0 0 1 0 0 0 1 0 0 0 2 6 0 10 
Enterococcus 
faecalis 0 0 0 3 0 1 0 1 0 0 1 2 10 0 18 
Escherichia coli 3 6 0 3 3 2 4 7 1 3 4 2 101 2 141 
Klebsiella 
pneumoniae 1 13 0 3 8 3 5 11 3 2 9 28 45 2 133 
Pseudomonas 
aeruginosa 3 6 0 0 15 2 3 11 4 2 0 12 10 5 73 
Staphylococcus 
aureus 1 2 0 0 2 0 8 3 0 0 3 45 9 0 73 
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Staphylococcus 
epidermidis 0 50 1 1 4 0 20 12 0 1 8 5 7 0 109 
Stenotrophomona
s maltophilia 0 2 0 0 7 2 0 2 2 1 1 5 2 0 24 
Streptococcus 
pneumoniae 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Streptococcus 
mitis 0 0 0 0 0 0 0 1 0 0 0 10 1 0 12 
Total 8 83 1 11 45 11 44 51 14 10 27 138 197 9 649 
 
a Sample distribution of multidrug pathogens by Hospital Unit mple distribution of 
multidrug 
 
 Table 9 Sample distribution of multidrug resistant pathogens by Hospital Unit 
Sample 
distribution 
of multidrug 
pathogens by 
Hospital Unit  
Mot
her 
ICU 
Neo
nato
logy 
ICU 
Pedi
atric 
ICU 
Uro
neph
rolo
gy 
Gyn
ecol
ogy 
Onc
olog
y 
Ther
apeu
tic 
Unit 
Rhe
uma
tolog
y 
Surg
ery 
Tota
l 
abdominal 
cavity 0 1 5 0 0 3 0 1 2 12 
blood 12 27 41 7 2 48 25 1 13 166 
breast milk 1 0 0 0 0 0 0 0 1 2 
cervix 1 0 3 0 45 1 3 1 1 55 
intubation 2 2 56 4 0 21 0 0 2 87 
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tube 
nasogastric 
tube 0 0 15 2 0 3 1 0 1 22 
nose 0 3 46 23 0 118 8 2 7 197 
pus/wound/ski
n 3 3 26 5 6 71 20 4 14 152 
sputum 4 1 17 11 1 10 26 4 2 76 
stool 0 1 12 2 0 2 0 0 1 18 
subclavian 
catheter 2 2 14 0 0 29 6 0 0 53 
throat 0 4 92 77 3 748 387 246 16 1573 
urine 22 0 52 252 18 86 33 7 23 493 
urine catheter 0 1 21 6 0 0 2 0 1 31 
Total 37 45 390 389 75 1140 511 266 84 2937 
 
 
Table 10 Resistance frequency of Gram-negative pathogens 
Resistance frequency of 
Gram -negative pathogens 
(n/% of multidrug 
resistant) 
Acineto
bacter 
bauman
ii 
Escheric
hia coli 
Klebsiell
a 
pneumon
iae 
Pseudom
onas 
aerugino
sa 
Stenotr
ophoma
s 
maltoph
ilia 
Ampicillin  
220/97.7
0 194/99.48 
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Cefazolin  
215/61.8
6 190/77.37 
Gentamycin 
82/17.0
7 217/9.22 
190/28.4
2 188/34.57 
Amoxicillin  
110/97.2
7 104/100  
Ceftazidime 82/31.71  
184/44.5
7 
40/60.0
0 
Piperacillin  
147/66.6
7 
148/75.6
8 173/32.95 
Trimetoprim/sulfametoxazo
l 79/37.97   40/2.50 
Doxycycline 82/15.85    
Tetracycline 81/16.05    
Piperacillin/Tazobactam 
84/11.9
0 211/1.40 189/4.76 185/11.35 
Piperacillin 42/28.57    
Amoxicillin/Clavulanate 
201/71.1
4 187/82.35 
Ampicillin/Sulbactam 
77/33.7
7 
192/64.5
8 184/76.09 
Cefepime 
82/29.2
7 
207/34.3
0 
191/53.4
0 192/32.81 
Cefotaxime 
82/35.3
7 
200/37.5
0 190/56.84 
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Meropenem 
83/13.2
5 195/2.56 187/5.88 181/16.02 
Ceftriaxone 
82/36.5
9 
196/38.2
7 184/56.52 
Ertapenem  168/1.79   
Aztreonam    179/25.70 
Amikacin 81/4.94 200/0.50 186/6.99 178/19.10 
Imipenem 
82/13.4
1 198/2.53 183/5.46 183/21.86 
Ciprofloxacin 
83/13.2
5 
197/14.7
2 184/9.24 183/15.30 
Cefuroxime 
197/50.2
5 183/68.85 
Ticarcillin/Clav 
81/44.4
4 
195/70.7
7 178/83.15 
39/76.9
2 
Levofloxacin 
81/12.3
5 
196/10.7
1 187/7.49 
183/14.2
1 39/0.00 
Lomefloxacin 93/23.66   
Tobramycin 26/11.54    
Nitrofurantoin 71/4.23   
Minocycline 27/11.12    
Norfloxacin 84/14.29 42/9.52 
Trimetoprim 84/66.67   
Chrloramfenicol    40/15.0
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0 
Ofloxacin  96/20.83 45/11.11 
 
Table 11 Resistance frequency of Gram-positive pathogens 
Resistance frequency of 
Gram-positive pathogens 
(n/% of multidrug 
resistant) 
Enteroco
ccus 
faecalis 
Staphylo
coccus 
aureus 
Streptoco
ccus 
epidermi
dis 
Streproc
occus 
mitis 
Strepro
coccus 
pneumo
niae 
Erithromycin 357/9.52 190/50.00 50/2.00 
Penicillin 
180/18.3
3 
385/97.4
0 
215/97.6
7 
1061/4.2
4 
50/12.0
0 
Oxacillin  386/5.70 214/21.49 
Clarithromycin 357/8.40 189/48.67 
Ampicillin 183/8.74 31/87.09 1068/1.22 
Gentamycin 61/6.57 96/11.46  
Azithromycin 359/8.65 190/48.42 
Amoxicillin 52/9.62 30/90.00 1063/0.47 
Clindamycin 337/3.56 183/23.50 46/6.52 
Trimetoprim/sulfametoxazo
l  381/6.04 213/48.35 
50/40.0
0 
Vancomycin 182/0.55 387/0.00 216/0.93 
1065/0.0
0 50/0.00 
Doxycycline 374/12.8 193/35.75 
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3 
Tetracycline 81/19.75 
386/12.9
5 211/33.18 50/4.00 
Linezolid 177/0.56 384/0.00 212/0.94  
Cefepime    
1040/0.8
7 49/0.00 
Cefotaxime   
1045/0.6
7 48/0.00 
Meropenem    49/0.00 
Ceftriaxone   
1041/0.6
7 49/0.00 
Ciprofloxacin 91/12.09 78/6.41 112/19.64 
Levofloxacin 91/5.49 78/5.13 112/11.61 50/0.00 
Moxifloxacin 74/1.35 104/2.88 49/0.00 
Nitrofurantoin 44/2.27    
Norfloxacin 72/25.00    
Chrloramfenicol 67/11.94 110/35.45 
Ofloxacin  52/5.77 83/18.07 47/0.00 
 
Table 12 Fungi multidrug resistance frequency 
Fungi resistance 
frequency (n/% of 
multidrug 
resistant) Candida albicans Candida tropicalis 
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Itraconazole 156/13.46 37/21.62 
Fluconazole 201/29.85 46/32.61 
Nystatin 203/0.00 47/0.00 
Clotrimazole 202/16.34 47/23.40 
Ketoconazole 201/21.89 46/21.74 
Amphotericin 177/1.13 43/11.63 
 
 
 
 
 
 
 
 
 
Table 13 Contingency table of age groups and their distribution 
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